View ValuationAtrium Therapeutics 향후 성장Future 기준 점검 0/6Atrium Therapeutics 의 수익과 수익은 각각 연간 78.3% 및 21.8% 감소할 것으로 예상됩니다 while EPS는 연간 9.1% 만큼 쇠퇴할 것으로 예상됩니다.핵심 정보-21.8%이익 성장률-9.10%EPS 성장률Biotechs 이익 성장27.2%매출 성장률-78.3%향후 자기자본이익률n/a애널리스트 커버리지Low마지막 업데이트14 Aug 2026최근 향후 성장 업데이트업데이트 없음모든 업데이트 보기Recent updates공고 • Jul 14Atrium Therapeutics Announces FDA Clearance Of Investigational New Drug Application For ATR 1072 For Treatment Of PRKAG2 SyndromeAtrium Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application allowing the Company to move forward with its Corventis Phase 1/2 clinical trial designed to evaluate ATR 1072 for the treatment of Protein Kinase AMP-activated non-catalytic subunit Gamma 2 (PRKAG2) syndrome. Corventis is a Phase 1/2 open-label, multicenter clinical trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of ATR 1072. The study will enroll approximately 37 participants across two parts: Part A, multiple ascending dose cohorts to characterize safety and support dose selection, and Part B, a single-arm expansion cohort at the recommended Phase 2 dose to further evaluate safety and efficacy trends in cardiac structure and function. Clinical site initiation activities are currently underway, and Atrium expects the first participant to be enrolled by the end of 2026. Initial trial data demonstrating proof of concept is anticipated in the second half of 2027. ATR 1072, the company's lead product candidate, is a potentially disease-modifying treatment for PRKAG2 syndrome. Using Atrium's precision RNA delivery technology, ATR 1072 uses small interfering RNA (siRNA) to silence mutant PRKAG2 messenger RNA (mRNA), normalize AMP-activated protein kinase (AMPK) activity and reduce pathogenic glycogen accumulation, potentially leading to improved heart function. PRKAG2 syndrome is a rare, autosomal dominant, early-onset cardiomyopathy caused by mutations in the PRKAG2 gene, which encodes the Gamma 2 regulatory subunit of AMPK. Mutations enhance AMPK activity leading to abnormal glycogen accumulation in the heart, thickened heart muscles, electrical conduction problems, and arrhythmias. Based on current scientific literature estimates, there are at least 1,000 – 2,000 people with PRKAG2 syndrome in the US. Current management is limited to symptomatic treatment; no approved therapies exist to address the underlying genetic driver of disease. Corventis is a Phase 1/2 open-label, multicenter clinical trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of ATR 1072 in participants living with PRKAG2 syndrome. The study will enroll approximately 37 participants across two parts: Part A, multiple ascending dose cohorts to characterize safety and support dose selection, and Part B, a single-arm expansion cohort at the recommended Phase 2 dose to further evaluate efficacy trends in cardiac structure and function.분석 기사 • Jun 16We're Hopeful That Atrium Therapeutics (NASDAQ:RNA) Will Use Its Cash WiselyJust because a business does not make any money, does not mean that the stock will go down. For example, although...Reported Earnings • May 17First quarter 2026 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2026 results: US$0.97 loss per share. Revenue: US$19.6m (up US$16.7m from 1Q 2025). Net loss: US$16.6m (loss widened 45% from 1Q 2025). Revenue exceeded analyst estimates significantly. Earnings per share (EPS) also surpassed analyst estimates by 7.6%. Revenue is expected to decline by 67% p.a. on average during the next 3 years, while revenues in the Biotechs industry in the US are expected to grow by 22%.New Risk • Mar 11New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 23% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings are forecast to decline by an average of 23% per year for the foreseeable future. Minor Risks Negative equity (-US$63m). Currently unprofitable and not forecast to become profitable over next 2 years (US$80m net loss in 2 years).Board Change • Mar 02No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Chair of the Board of Director Sarah Boyce was the last director to join the board, commencing their role in 2025. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.공고 • Feb 28Atrium Therapeutics Launches with Approximately $270 Million to Advance Novel Rna Medicines for Rare Genetic CardiomyopathiesAtrium Therapeutics, Inc. launched as a newly independent, publicly traded company dedicated to delivering RNA therapeutics directly to the heart to transform care for people living with rare, life-threatening genetic cardiomyopathies. Atrium Therapeutics was established in connection with Avidity Biosciences, Inc.'s acquisition by Novartis AG. ATR 1086 (PLN cardiomyopathy): Chemistry Manufacturing and Controls (CMC) manufacturing planned to support initiation of IND-enabling preclinical studies in 2026, targeting an IND submission in 2027. Pending supportive Phase 1 trial results, Atrium Therapeutics anticipates advancing both programs into clinical trials, while continuing to expand its additional precision cardiology pipeline and develop its next-generation RNA delivery platform.이익 및 매출 성장 예측NasdaqGS:RNA - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/2028N/A-139-90-86212/31/20272-122-70-79412/31/202634-78-51-8646/30/202636-66-57-53N/A3/31/202637-59-65-61N/A12/31/202519-50-43-41N/A9/30/202521-32-31-30N/A12/31/202411-25-23-23N/A12/31/202310-65656N/A애널리스트 향후 성장 전망수입 대 저축률: RNA 향후 3년 동안 수익성이 없을 것으로 예상됩니다.수익 vs 시장: RNA 향후 3년 동안 수익성이 없을 것으로 예상됩니다.고성장 수익: RNA 향후 3년 동안 수익성이 없을 것으로 예상됩니다.수익 대 시장: RNA 의 수익은 향후 3년간 감소할 것으로 예상됩니다(연간 -78.3%).고성장 매출: RNA 의 수익은 향후 3년 동안 감소할 것으로 예상됩니다(연간 -78.3%).주당순이익 성장 예측향후 자기자본이익률미래 ROE: RNA의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/08/19 15:47종가2026/08/19 00:00수익2026/06/30연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Atrium Therapeutics, Inc.는 4명의 분석가가 다루고 있습니다. 이 중 4명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Kristen KluskaCantor Fitzgerald & Co.Mitchell KapoorH.C. Wainwright & Co.Joseph SchwartzLeerink Partners LLC1명의 분석가 더 보기
공고 • Jul 14Atrium Therapeutics Announces FDA Clearance Of Investigational New Drug Application For ATR 1072 For Treatment Of PRKAG2 SyndromeAtrium Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application allowing the Company to move forward with its Corventis Phase 1/2 clinical trial designed to evaluate ATR 1072 for the treatment of Protein Kinase AMP-activated non-catalytic subunit Gamma 2 (PRKAG2) syndrome. Corventis is a Phase 1/2 open-label, multicenter clinical trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of ATR 1072. The study will enroll approximately 37 participants across two parts: Part A, multiple ascending dose cohorts to characterize safety and support dose selection, and Part B, a single-arm expansion cohort at the recommended Phase 2 dose to further evaluate safety and efficacy trends in cardiac structure and function. Clinical site initiation activities are currently underway, and Atrium expects the first participant to be enrolled by the end of 2026. Initial trial data demonstrating proof of concept is anticipated in the second half of 2027. ATR 1072, the company's lead product candidate, is a potentially disease-modifying treatment for PRKAG2 syndrome. Using Atrium's precision RNA delivery technology, ATR 1072 uses small interfering RNA (siRNA) to silence mutant PRKAG2 messenger RNA (mRNA), normalize AMP-activated protein kinase (AMPK) activity and reduce pathogenic glycogen accumulation, potentially leading to improved heart function. PRKAG2 syndrome is a rare, autosomal dominant, early-onset cardiomyopathy caused by mutations in the PRKAG2 gene, which encodes the Gamma 2 regulatory subunit of AMPK. Mutations enhance AMPK activity leading to abnormal glycogen accumulation in the heart, thickened heart muscles, electrical conduction problems, and arrhythmias. Based on current scientific literature estimates, there are at least 1,000 – 2,000 people with PRKAG2 syndrome in the US. Current management is limited to symptomatic treatment; no approved therapies exist to address the underlying genetic driver of disease. Corventis is a Phase 1/2 open-label, multicenter clinical trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of ATR 1072 in participants living with PRKAG2 syndrome. The study will enroll approximately 37 participants across two parts: Part A, multiple ascending dose cohorts to characterize safety and support dose selection, and Part B, a single-arm expansion cohort at the recommended Phase 2 dose to further evaluate efficacy trends in cardiac structure and function.
분석 기사 • Jun 16We're Hopeful That Atrium Therapeutics (NASDAQ:RNA) Will Use Its Cash WiselyJust because a business does not make any money, does not mean that the stock will go down. For example, although...
Reported Earnings • May 17First quarter 2026 earnings: EPS and revenues exceed analyst expectationsFirst quarter 2026 results: US$0.97 loss per share. Revenue: US$19.6m (up US$16.7m from 1Q 2025). Net loss: US$16.6m (loss widened 45% from 1Q 2025). Revenue exceeded analyst estimates significantly. Earnings per share (EPS) also surpassed analyst estimates by 7.6%. Revenue is expected to decline by 67% p.a. on average during the next 3 years, while revenues in the Biotechs industry in the US are expected to grow by 22%.
New Risk • Mar 11New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 23% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings are forecast to decline by an average of 23% per year for the foreseeable future. Minor Risks Negative equity (-US$63m). Currently unprofitable and not forecast to become profitable over next 2 years (US$80m net loss in 2 years).
Board Change • Mar 02No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Chair of the Board of Director Sarah Boyce was the last director to join the board, commencing their role in 2025. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
공고 • Feb 28Atrium Therapeutics Launches with Approximately $270 Million to Advance Novel Rna Medicines for Rare Genetic CardiomyopathiesAtrium Therapeutics, Inc. launched as a newly independent, publicly traded company dedicated to delivering RNA therapeutics directly to the heart to transform care for people living with rare, life-threatening genetic cardiomyopathies. Atrium Therapeutics was established in connection with Avidity Biosciences, Inc.'s acquisition by Novartis AG. ATR 1086 (PLN cardiomyopathy): Chemistry Manufacturing and Controls (CMC) manufacturing planned to support initiation of IND-enabling preclinical studies in 2026, targeting an IND submission in 2027. Pending supportive Phase 1 trial results, Atrium Therapeutics anticipates advancing both programs into clinical trials, while continuing to expand its additional precision cardiology pipeline and develop its next-generation RNA delivery platform.